Angiotech Pharmaceuticals (ANP-T) Stock Predictions - Stockchase
WATCH LIST
140
Angiotech Pharmaceuticals (ANP-T)

ON STOCKCHASE SINCE Apr 2001

Bankrupt?

biotechnology/pharmaceutical

Angiotech Pharmaceuticals

ANP-T

2 watching          
Join the Discussion

Angiotech Pharmaceuticals (ANP-T) SAVE Dec, 31, 1969, 7:00 pm

0.00 0 (100%)

This company is not ACTIVE.

What the experts are saying about ANP-T



  • All
  • Filtered
Signal Opinion Expert
DON'T BUY
What hurts them was they levered up for an acquisition using debt at the wrong time and have never been able to get out from under that cloud of debt and he doesn't think they will.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
What hurts them was they levered up for an acquisition using debt at the wrong time and have never been able to get out from under that cloud of debt and he doesn't think they will.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
John Zechner

Chairman, J. Zechner & Assoc...

Price Price
$1.210
Owned Owned
No

BUY on WEAKNESS
(Market Call Minute.) A lot of biotech stocks have done well. Would buy on a pullback.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
(Market Call Minute.) A lot of biotech stocks have done well. Would buy on a pullback.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Robert McWhirte

President, Selective Asset Mana...

Price Price
$1.900
Owned Owned
Unknown

DON'T BUY
Had 2 approvals, May 27 and June 8. This is on his Watch list but was far more interesting before May 27 so it now holds no interest for him. Might be okay for momentum players.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Had 2 approvals, May 27 and June 8. This is on his Watch list but was far more interesting before May 27 so it now holds no interest for him. Might be okay for momentum players.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Benj Gallander

President, Contra the Heard Inv...

Price Price
$2.150
Owned Owned
No

COMMENT
The stock has been hurt, but it is more of an issue because of stents. Sales projections are falling off. At this stage, you are probably facing tax loss selling for the rest of the month and then get a January bounce if the company has a decent outlook going forward. Competition has increased in this area.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
The stock has been hurt, but it is more of an issue because of stents. Sales projections are falling off. At this stage, you are probably facing tax loss selling for the rest of the month and then get a January bounce if the company has a decent outlook going forward. Competition has increased in this area.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Robert Floyd

President, R A Floyd Management...

Price Price
$3.660
Owned Owned
No

HOLD
Have had serious problems with their stents. The whole area is having issues. Excellent management. They have big pipeline and the technology is still excellent.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Have had serious problems with their stents. The whole area is having issues. Excellent management. They have big pipeline and the technology is still excellent.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Chyanne Fickes

Vice Presi, Stone Funds...

Price Price
$7.310
Owned Owned
Unknown

SELL
The whole market is going up, and this one is going down. Let someone else own it.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
The whole market is going up, and this one is going down. Let someone else own it.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Kenneth P. Norq

Partner, Castlemoore Inc....

Price Price
$7.220
Owned Owned
No

SELL
A one trick pony with its coated stent. There is lots of controversy on drug coated stents.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
A one trick pony with its coated stent. There is lots of controversy on drug coated stents.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Norman Levine

Managing D, Portfolio Management...

Price Price
$6.290
Owned Owned
No

DON'T BUY
They're very focused on one part of the business, which is stents. There is a lot of competition in this sector. Revenue projections have been dropping.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
They're very focused on one part of the business, which is stents. There is a lot of competition in this sector. Revenue projections have been dropping.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Robert Floyd

President, R A Floyd Management...

Price Price
$6.850
Owned Owned
Unknown

COMMENT
Makes drug alluding stents. Its penetration rate in the US was 75% but has dropped to 65%. Will be launching in Japan in the fall. Have a lot of debt on the balance sheet and are in the process of selling assets.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Makes drug alluding stents. Its penetration rate in the US was 75% but has dropped to 65%. Will be launching in Japan in the fall. Have a lot of debt on the balance sheet and are in the process of selling assets.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Chyanne Fickes

Vice Presi, Stone Funds...

Price Price
$6.990
Owned Owned
Unknown

BUY
The worst news is already in the stock. At these levels, it's a Buy. Have product pipeline starting to develop. Looking at drug eluding stents in the Japanese market.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
The worst news is already in the stock. At these levels, it's a Buy. Have product pipeline starting to develop. Looking at drug eluding stents in the Japanese market.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
John Zechner

Chairman, J. Zechner & Assoc...

Price Price
$6.170
Owned Owned
Yes

DON'T BUY
A “ one trick pony”. There are now lots of questions to the effectiveness of drug-coated stents.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
A “ one trick pony”. There are now lots of questions to the effectiveness of drug-coated stents.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Norman Levine

Managing D, Portfolio Management...

Price Price
$6.380
Owned Owned
No

DON'T BUY
Not time to buy this one yet. They have the stent problem and the adoption problem. Lowering their earnings forecasts. Potential recovery, but wait for the recovery.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Not time to buy this one yet. They have the stent problem and the adoption problem. Lowering their earnings forecasts. Potential recovery, but wait for the recovery.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Peter Hodson

CEO & Head, 5i Research Inc....

Price Price
$7.200
Owned Owned
No

DON'T BUY
Had a long-term problem with stents. Made a series of acquisitions which all look very interesting. Not sure what the effect of this will be. A raving buy at this price, but does not like buying a stock on the way down.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Had a long-term problem with stents. Made a series of acquisitions which all look very interesting. Not sure what the effect of this will be. A raving buy at this price, but does not like buying a stock on the way down.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Chyanne Fickes

Vice Presi, Stone Funds...

Price Price
$7.200
Owned Owned
Yes

DON'T BUY
If it breaks $7.35, it is going to go lower. His model price is hugely coming down. In September it was $16 and now it is $10.73, which is a positive differential, but earnings are dropping.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
If it breaks $7.35, it is going to go lower. His model price is hugely coming down. In September it was $16 and now it is $10.73, which is a positive differential, but earnings are dropping.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Brian Acker, CA

Chief Exec, Acker Finley Inc....

Price Price
$7.370
Owned Owned
No

DON'T BUY
Guidance for this year was quite poor. Their stent business is not going to be as robust. Company needs to diversify their asset base and have been slow to do that.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Guidance for this year was quite poor. Their stent business is not going to be as robust. Company needs to diversify their asset base and have been slow to do that.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Robert Floyd

President, R A Floyd Management...

Price Price
$7.830
Owned Owned
Unknown

Showing 1 to 15 of 140 entries
Successfully Saved Company
Successfully Saved Company
4+
JOIN THE DISCUSSION
4 comments in the last 7 days